Kantoff-Sang Lecture Series – Regulatory Science: Perspectives – May 2, 2013

Regulatory science, as defined by the Food and Drug Administration (FDA) in a recent 2010 publication from the Institute of Medicine (IOM) entitled Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development, is the “science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products.”

This symposium will include seven presentations by the leaders in the field:

  • Janet Woodcock, MD, FDA
  • Scott Gottlieb, MD, American Enterprise Institute
  • Elliott Antman, MD, Brigham and Women’s Hospital
  • William Chin, MD, Harvard Medical School
  • Elazer Edelman, MD, PhD, MIT
  • Michael Rosenblatt, M.D, Merck & Co.,Inc.
  • Daniel Carpenter, PhD, Harvard University 

Following presentations, the audience will be invited to explore these topics further during an hour-long panel moderated by Joshua Boger, PhD. Reception to follow.

When: May 2, 2013, 4:00-7:00pm

Where: Harvard Medical School
Armenise Amphitheater
200 Longwood Avenue

Boston, MA 02115

Space is limited, so please register here. Contact us if you have any questions.

Members of the academic and pharmaceutical industries are welcome to attend.